Skip to main content

Establishment profile

TEVA PHARMACEUTICALS USA

1090 HORSHAM ROAD, NORTH WALES, PA, 19454
Operated by TEVA PHARMACEUTICAL INDUSTRIES LTD · 1 of 29 establishments
325412Pharmaceutical Preparation Manufacturing
EIN 221734359

Download as PDF →

OSHA inspections
1
over 11 years
Violations
0
Penalties
$0
Accident investigations on record
1 National Emphasis Program inspections

Summary

TEVA PHARMACEUTICALS USA has accumulated 0 OSHA violations across 1 inspection over 11 years of recorded history.

The most recent federal enforcement activity was recorded 11 years ago.

Federal records were found in 2 of 15 sources. Sources without matching records returned empty for this establishment.

Agency coverage

TEVA PHARMACEUTICALS USA appears in OSHA workplace safety and UVA Corporate Prosecution Registry records only. No matching records were found in WHD wage enforcement, MSHA mine safety, EPA environmental compliance, NLRB labor relations, OFLC visa and labor certification (historical), FMCSA motor carrier registration, SAM.gov federal debarment, CMS nursing home enforcement, CPSC product recalls, or NHTSA vehicle recalls.

OSHA workplace safety

Inspections
1
0.1 / yr · last 11 yrs
Violations
0
0.0 / yr
Penalties
$0
Inspection trigger · planned
1 of 1

Peer comparison

0th

Fewer violations than most other employers in NAICS 3254 within PA. Peer group: 93 employers. This establishment has 0 OSHA violations; peer median is 0.

Fewer violationsMore violations
Penalty percentile
0th
peer median: $0
Inspection frequency
0th
peer median: 1

Safety self-report (OSHA 300A)

Recordable injury rates the employer filed with OSHA’s Injury Tracking Application. DART covers cases with days away, restricted, or transferred; TRIR is the total recordable case rate.

DART rate
0.0
vs industry
−0.9
TRIR
0.0
vs industry
−1.4

Reported for 24 average annual employees at this establishment.

Source: OSHA ITA Form 300A (employer self-reported). Rates are per 100 full-time equivalent workers. Establishments below the ~10-FTE threshold are not required to report.

Industry benchmark

Industry avg TRIR
1.4
BLS SOII 2024
Industry avg DART
0.9
BLS SOII 2024
Self-reported TRIR
0.0
OSHA ITA Form 300A (employer self-reported)

BLS rates reflect industry-wide averages. Self-reported figures come from OSHA’s Injury Tracking Application; absence of self-reported data does not necessarily indicate non-compliance — many establishments fall below the ITA reporting threshold.

Inspection breakdown

Planned
1

Complaint- and accident-triggered inspections are stronger risk signals than routine planned inspections.

OSHA severe injury reports

No severe injury reports (hospitalization, amputation, or loss of an eye) on file under 29 CFR 1904.39 for TEVA PHARMACEUTICALS USA. Verify directly with Occupational Safety and Health Administration

Activity timeline

Data refreshed
Weekly
First OSHA inspection
Most recent activity
11 years ago

No federal enforcement activity has been recorded against this establishment in 11+ years. Most recent activity: 11 years ago. Data on this page is refreshed weekly.

Wage & Hour Division (WHD)

No WHD wage, overtime, or child-labor enforcement cases on file for TEVA PHARMACEUTICALS USA. Verify directly with Wage and Hour Division

Mine safety (MSHA)

No MSHA mine safety violations on file for TEVA PHARMACEUTICALS USA. Verify directly with Mine Safety and Health Administration

Labor relations (NLRB)

No NLRB unfair labor practice charges or union representation cases on file for TEVA PHARMACEUTICALS USA. Verify directly with National Labor Relations Board

Visa & labor certification (OFLC) — historical

No H-1B, H-2A, or H-2B labor condition applications on file (historical data only — DOL ended OFLC publication) for TEVA PHARMACEUTICALS USA. Verify directly with Office of Foreign Labor Certification

Environmental compliance (EPA)

No EPA inspections or formal enforcement actions on file for TEVA PHARMACEUTICALS USA. Verify directly with Environmental Protection Agency

Federal criminal prosecution record

Prosecutions
1
Total payments
$225.0M
Disposition
DP
Crime type
Antitrust

First case: 2023-08-21. Most recent: 2023-08-21. Source: UVA Corporate Prosecution Registry — federal pleas, DPAs, and NPAs.

Federal prosecution case file

Federal corporate prosecution records from the University of Virginia Corporate Prosecution Registry. DPA = Deferred Prosecution Agreement; NPA = Non-Prosecution Agreement; both are pre-trial settlements where the defendant accepts terms but avoids conviction. Monitor = court-appointed compliance oversight, usually 2-5 years. 1 case · $225,000,000 in penalties / restitution.

CaseDateDispositionCrimeJurisdictionTotal paymentMonitor
Teva Pharmaceuticals USA, Inc.
Aug 2023DPAntitrustUSDOJ - Antitrust Division$225,000,000No

Source: University of Virginia Corporate Prosecution Registry (maintained by Prof. Brandon L. Garrett, Duke University). The registry has no state or jurisdiction-of-incorporation field on the company side, so same-name employers in different states may mis-attribute -- verify against the source case documents when precision matters.

Federal contracts

This location

Obligated (5-yr)
$160.3M
Obligated (all-time)
$233.3M
Awards
641
Top agency
Department of Defense
$229.9M
Company-wide — TEVA PHARMACEUTICAL INDUSTRIES LTD. (across 7 entities)
Obligated (5-yr)
$77.6M
Obligated (all-time)
$412.1M
Awards (all-time)
833

Consolidated across all USAspending recipient entities under this corporate parent — not attributable to this single location.

Top agencies by obligation (this location)
Department of Defense$229.9M
Department of Veterans Affairs$2.4M
Department of Health and Human Services$1.0M
Largest awards (top 50 of 641)
  • Department of Defense
    8511147946!ADENOVIRUS TYPE 4 A
    contract · Last action 2025-01-28
    $5,285,022
  • Department of Defense
    8511856699!ADENOVIRUS TYPE 4 A
    contract · Last action 2026-01-13
    $3,950,554
  • Department of Defense
    8511009796!ADENOVIRUS TYPE 4 A
    contract · Last action 2024-11-14
    $3,176,095
  • Department of Defense
    8510325537!ADENOVIRUS TYPE 4 A
    contract · Last action 2023-12-14
    $2,443,150
  • Department of Defense
    contract · Last action 2017-02-17
    $2,269,470
  • Department of Defense
    8511784063!ADENOVIRUS TYPE 4 A
    contract · Last action 2025-12-01
    $1,981,883
  • Department of Defense
    8510559015!ADENOVIRUS TYPE 4 A
    contract · Last action 2024-04-09
    $1,588,047
  • Department of Defense
    8510325475!ADENOVIRUS TYPE 4 A
    contract · Last action 2023-12-14
    $1,526,969
  • Department of Defense
    8510766857!ADENOVIRUS TYPE 4 A
    contract · Last action 2024-07-19
    $1,429,243
  • Department of Defense
    8510688482!ADENOVIRUS TYPE 4 A
    contract · Last action 2024-06-13
    $1,429,243
  • Department of Defense
    8510634433!ADENOVIRUS TYPE 4 A
    contract · Last action 2024-05-15
    $1,429,243
  • Department of Defense
    8507666472!ADENOVIRUS TYPE 4 A
    contract · Last action 2020-09-21
    $1,357,470
  • Department of Defense
    8507666398!ADENOVIRUS TYPE 4 A
    contract · Last action 2020-09-21
    $1,357,470
  • Department of Defense
    8511784064!ADENOVIRUS TYPE 4 A
    contract · Last action 2025-12-01
    $1,321,255
  • Department of Defense
    8510902080!ADENOVIRUS TYPE 4 A
    contract · Last action 2024-09-18
    $1,270,438
  • Department of Defense
    8510401601!ADENOVIRUS TYPE 4 A
    contract · Last action 2024-01-25
    $1,270,438
  • Department of Defense
    8507666399!ADENOVIRUS TYPE 4 A
    contract · Last action 2020-09-21
    $1,221,723
  • Department of Defense
    8507153551!ADENOVIRUS TYPE 4 A
    contract · Last action 2020-02-07
    $1,221,723
  • Department of Defense
    8511565495!ADENOVIRUS TYPE 4 A
    contract · Last action 2025-08-12
    $1,156,099
  • Department of Defense
    8511148052!ADENOVIRUS TYPE 4 A
    contract · Last action 2025-01-28
    $1,156,099
  • Department of Defense
    8510839749!ADENOVIRUS TYPE 4 A
    contract · Last action 2024-08-22
    $1,111,633
  • Department of Defense
    8510500489!ADENOVIRUS TYPE 4 A
    contract · Last action 2024-03-13
    $1,111,633
  • Department of Defense
    8507153570!ADENOVIRUS TYPE 4 A
    contract · Last action 2020-02-07
    $1,085,976
  • Department of Defense
    8509568637!ADENOVIRUS TYPE 4 A
    contract · Last action 2022-12-06
    $1,027,768
  • Department of Defense
    8509567884!ADENOVIRUS TYPE 4 A
    contract · Last action 2022-12-06
    $1,027,768
  • Department of Defense
    8511369471!ADENOVIRUS TYPE 4 A
    contract · Last action 2025-05-12
    $990,942
  • Department of Defense
    8511296118!ADENOVIRUS TYPE 4 A
    contract · Last action 2025-04-07
    $990,942
  • Department of Defense
    8511229343!ADENOVIRUS TYPE 4 A
    contract · Last action 2025-03-06
    $990,942
  • Department of Defense
    8508275916!ADENOVIRUS TYPE 4 A
    contract · Last action 2021-06-08
    $988,238
  • Department of Defense
    8510462163!ADENOVIRUS TYPE 4 A
    contract · Last action 2024-02-22
    $952,828
  • Department of Defense
    8507666471!ADENOVIRUS TYPE 4 A
    contract · Last action 2020-09-21
    $950,229
  • Department of Defense
    8507538016!ADENOVIRUS TYPE 4 A
    contract · Last action 2020-07-22
    $950,229
  • Department of Defense
    8507395371!ADENOVIRUS TYPE 4 A
    contract · Last action 2020-05-21
    $950,229
  • Department of Defense
    8507153556!ADENOVIRUS TYPE 4 A
    contract · Last action 2020-02-07
    $950,229
  • Department of Defense
    8510325476!ADENOVIRUS TYPE 4 A
    contract · Last action 2023-12-14
    $916,181
  • Department of Defense
    8510093039!ADENOVIRUS TYPE 4 A
    contract · Last action 2023-08-22
    $916,181
  • Department of Defense
    8510016515!ADENOVIRUS TYPE 4 A
    contract · Last action 2023-07-18
    $916,181
  • Department of Defense
    8510016965!ADENOVIRUS TYPE 4 A
    contract · Last action 2023-07-18
    $916,181
  • Department of Defense
    8509963743!ADENOVIRUS TYPE 4 A
    contract · Last action 2023-06-20
    $916,181
  • Department of Defense
    8508509762!ADENOVIRUS TYPE 4 A
    contract · Last action 2021-09-09
    $847,061
  • Department of Defense
    8508432581!ADENOVIRUS TYPE 4 A
    contract · Last action 2021-08-11
    $847,061
  • Department of Defense
    8508191759!ADENOVIRUS TYPE 4 A
    contract · Last action 2021-05-06
    $847,061
  • Department of Defense
    8511624235!ADENOVIRUS TYPE 4 A
    contract · Last action 2025-09-08
    $825,785
  • Department of Defense
    8511624191!ADENOVIRUS TYPE 4 A
    contract · Last action 2025-09-08
    $825,785
  • Department of Defense
    8511624231!ADENOVIRUS TYPE 4 A
    contract · Last action 2025-09-08
    $825,785
  • Department of Defense
    8511565494!ADENOVIRUS TYPE 4 A
    contract · Last action 2025-08-12
    $825,785
  • Department of Defense
    8511499274!ADENOVIRUS TYPE 4 A
    contract · Last action 2025-07-14
    $825,785
  • Department of Defense
    8511499119!ADENOVIRUS TYPE 4 A
    contract · Last action 2025-07-14
    $825,785
  • Department of Defense
    8511499116!ADENOVIRUS TYPE 4 A
    contract · Last action 2025-07-14
    $825,785
  • Department of Defense
    8511446666!ADENOVIRUS TYPE 4 A
    contract · Last action 2025-06-16
    $825,785

Federal contract dollars to this establishment. Primary NAICS: 325412 - PHARMACEUTICAL PREPARATION MANUFACTURING. Last action: 2026-04-10. Source: USAspending.gov, net obligations. Recipient address is the SAM registration / HQ address, not necessarily the worksite.

Inspection history

DateTriggerViolationsSeriousPenalty
2015-07-09Planned0$0

Source: OSHA IMIS. Citation amounts reflect initially assessed penalties; final amounts after appeal may differ.

In the news

Part of a larger organization

TEVA PHARMACEUTICALS USA is one of 29 establishments rolled up under the parent organization TEVA PHARMACEUTICAL INDUSTRIES LTD.

Federal enforcement records on this page represent activity at this specific establishment only. The full enforcement footprint of TEVA PHARMACEUTICAL INDUSTRIES LTD across all 29 of its tracked locations is viewable on the parent profile.

Other employers in this industry and state

Other employers in pharmaceutical preparation manufacturing within PA, ordered by federal enforcement volume:

Other locations under this parent

Other establishments operated by TEVA PHARMACEUTICAL INDUSTRIES LTD, ordered by federal enforcement volume:

Related searches

About this data

This profile aggregates federal enforcement records on TEVA PHARMACEUTICALS USA from every major federal compliance and enforcement source plus the UVA Corporate Prosecution Registry. OSHA workplace safety inspections, WHD wage cases, MSHA mine safety, EPA environmental enforcement, NLRB labor relations, OFLC visa/labor certification, FMCSA motor carrier registration, SAM.gov debarments, CMS nursing-home records, BLS industry safety benchmarks, OSHA ITA self-reported injury rates, SEC enforcement and financial disclosures, CPSC and NHTSA recalls.

Establishments are matched across agencies using normalized employer name, state, and ZIP code. This establishment resolves to the parent rollup TEVA PHARMACEUTICAL INDUSTRIES LTD, which operates 29 establishments in our dataset.

OSHA citations typically appear 3–8 months after the inspection, so very recent enforcement actions may not yet be reflected. Profiles may be incomplete if the establishment operates under multiple legal names or files under variations our entity-matching rules don’t yet cover. To report a missing record or correction, email corrections@fastdol.com.

Need API access, bulk download, or licensed redistribution? The website is free. Programmatic and licensed access is handled separately.

Contact sales →

Frequently asked

What is TEVA PHARMACEUTICALS USA's OSHA violation history?
TEVA PHARMACEUTICALS USA has 1 OSHA inspection on record with 0 violations and $0 in total penalties.
How does TEVA PHARMACEUTICALS USA's safety record compare to its industry?
TEVA PHARMACEUTICALS USA operates in the pharmaceutical preparation manufacturing industry. The industry average Total Recordable Incident Rate (TRIR) is 1.4. TEVA PHARMACEUTICALS USA's self-reported DART rate is 0 compared to an industry average of 0.9.